Malignancy risk in adults with growth hormone deficiency undergoing long-term treatment with biosimilar somatropin (Omnitrope
adult growth hormone deficiency
incidence
malignancies
recombinant human growth hormone
risk
Journal
Therapeutic advances in endocrinology and metabolism
ISSN: 2042-0188
Titre abrégé: Ther Adv Endocrinol Metab
Pays: United States
ID NLM: 101532143
Informations de publication
Date de publication:
2020
2020
Historique:
received:
13
03
2020
accepted:
29
06
2020
entrez:
25
9
2020
pubmed:
26
9
2020
medline:
26
9
2020
Statut:
epublish
Résumé
To assess the safety (particularly the occurrence of malignancies) of growth hormone (GH) replacement (Omnitrope PATRO Adults is being conducted in hospitals and specialized endocrinology clinics across Europe. All enrolled patients who receive ⩾1 dose of Omnitrope As of July 2018, 1293 patients had been enrolled in the study and 983 (76.0%) remained active in the study. Approximately half [ Based on this snapshot of data from PATRO Adults, Omnitrope
Sections du résumé
BACKGROUND
BACKGROUND
To assess the safety (particularly the occurrence of malignancies) of growth hormone (GH) replacement (Omnitrope
METHODS
METHODS
PATRO Adults is being conducted in hospitals and specialized endocrinology clinics across Europe. All enrolled patients who receive ⩾1 dose of Omnitrope
RESULTS
RESULTS
As of July 2018, 1293 patients had been enrolled in the study and 983 (76.0%) remained active in the study. Approximately half [
CONCLUSION
CONCLUSIONS
Based on this snapshot of data from PATRO Adults, Omnitrope
Identifiants
pubmed: 32973992
doi: 10.1177/2042018820943377
pii: 10.1177_2042018820943377
pmc: PMC7491215
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2042018820943377Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: CH has acted as an investigator for Sandoz, Pfizer, and NovoNordisk; has received lecture fees from Sandoz, Pfizer, and NovoNordisk; and is a member of the global steering committee for the PATRO Adults study. RDM has received research funding from Sandoz, Ipsen, and Pfizer; has received lecture fees from Pfizer; and is a member of the global steering committee for the PATRO Adults study. PBP and SS are members of the global steering committee for the PATRO Adults study. GS has received honoraria for scientific advisory work and/or reimbursement of delegate fees for congresses/seminars and/or travel costs and/or research grants from the HRA, Ipsen, Lilly, Novartis, NovoNordisk, Pfizer, Sandoz, and Shire; and is a member of the global steering committee for the PATRO Adults study. HM and MZ are employees of Sandoz Biopharmaceutical/Hexal AG.
Références
Clin Endocrinol (Oxf). 2018 Apr;88(4):515-528
pubmed: 29055168
Clin Endocrinol (Oxf). 2006 Feb;64(2):122-4
pubmed: 16430707
J Clin Endocrinol Metab. 2011 Jun;96(6):1587-609
pubmed: 21602453
J Clin Endocrinol Metab. 2017 May 1;102(5):1661-1672
pubmed: 28187225
Growth Horm IGF Res. 2011 Feb;21(1):1-10
pubmed: 21093334
Eur J Endocrinol. 2007 Dec;157(6):695-700
pubmed: 18057375
Cancer. 2018 Jul 1;124(13):2785-2800
pubmed: 29786848
Expert Rev Endocrinol Metab. 2011 Jan;6(1):71-84
pubmed: 30764037
J Clin Endocrinol Metab. 2001 May;86(5):1868-70
pubmed: 11344173
J Clin Endocrinol Metab. 2018 Feb 1;103(2):523-531
pubmed: 29228199
Clin Endocrinol (Oxf). 2006 Feb;64(2):115-21
pubmed: 16430706
Ther Adv Endocrinol Metab. 2012 Jun;3(3):85-91
pubmed: 23148199
Eur J Endocrinol. 2016 Feb;174(2):P1-9
pubmed: 26563978
Clin Endocrinol (Oxf). 2014 Jul;81(1):1-14
pubmed: 24750271
Growth Horm IGF Res. 2015 Aug;25(4):149-57
pubmed: 26117668
J Clin Endocrinol Metab. 2013 Mar;98(3):980-8
pubmed: 23345098
Int J Mol Sci. 2018 Mar 17;19(3):
pubmed: 29562611
Eur J Endocrinol. 2013 Oct 01;169(5):R89-97
pubmed: 23935131
Best Pract Res Clin Endocrinol Metab. 2017 Feb;31(1):35-47
pubmed: 28477731